At a glance
- Originator GlaxoSmithKline
- Class Antiarrhythmics; Antihypertensives; Ischaemic heart disorder therapies
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 05 Jan 2000 Profile reviewed but no significant changes made
- 26 Jan 1995 Preclinical development for Hyperlipidaemia in United Kingdom (Unknown route)